Economic impact of industry-sponsored clinical trials in inflammatory bowel diseases: Results from the national institute of gastroenterology "Saverio de Bellis".

Autor:	Polignano MG; Scientific Management Department, IRCCS National Institute of Research 'Saverio De Bellis', Bari, Italy., Pasculli G; Department of Computer, Control, and Management Engineering Antonio Ruberti (DIAG) Sapienza University, Rome, Italy., Trisolini P; IRCCS National Institute of Research 'Saverio De Bellis', Bari, Italy., Di Lorenzo MA; Scientific Management Department, IRCCS National Institute of Research 'Saverio De Bellis', Bari, Italy., Dalfino G; Scientific Management Department, IRCCS National Institute of Research 'Saverio De Bellis', Bari, Italy., Giannelli G; Scientific Management Department, IRCCS National Institute of Research 'Saverio De Bellis', Bari, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2022 Nov 22; Vol. 13, pp. 1027760. Date of Electronic Publication: 2022 Nov 22 (Print Publication: 2022).
DOI:	10.3389/fphar.2022.1027760
Abstrakt:	Introduction: The majority of the money spent on possible new medications' clinical trials is accounted for by the innovative pharmaceutical sector, which also stimulates the economy of a nation. The objective of this study was to evaluate the impact of pharmaceutical industry-sponsored clinical trials (ISCTs) in inflammatory bowel diseases (IBDs) towards the national health service (NHS) in terms of avoided costs and leverage effect. Methodology: The research was conducted at National Institute of Gastroenterology, "Saverio De Bellis", Castellana Grotte (Apulia, Italy) collecting data from profit ISCTs of pharmaceutical products conducted over the time period 2018-2020 with focus on inflammatory bowel diseases. After the quantification of health services and drug costs from the latter studies, avoided costs and leverage effects were then estimated. Results: The results on the avoided costs for healthcare facilities deriving from the conduct of clinical studies show that, in relation to the sample of five drug companies participating in our 2018-2020 analysis, out of a total of 235,102.46 €, identified as direct investment, 628,158.21 € of avoided costs for the NHS were measured, with an additional saving (leverage effect) for the NHS of 3.67 € for each € invested by the companies promoting clinical trials. Conclusion: Conducting profit clinical trials has practical benefits and a favourable macroeconomic impact that, by completing its limited resources, helps to sustain one country NHS thanks to the avoided costs while also contributing to locational and industrial policy while guaranteeing novel therapeutics and health services for the patients enrolled. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Polignano, Pasculli, Trisolini, Di Lorenzo, Dalfino and Giannelli.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu